← Back to All US Stocks

RDGL Stock Analysis 2026 - VIVOS INC AI Rating

RDGL OTC Surgical & Medical Instruments & Apparatus DE CIK: 0001449349
Recently Updated • Analysis: Apr 8, 2026 • SEC Data: 2025-12-31
Combined AI Rating
STRONG SELL
88% Confidence
STRONG AGREEMENT
STRONG SELL
95% Conf
STRONG SELL
82% Conf

📊 RDGL Key Takeaways

Revenue: $68.4K
Net Margin: -4,483.9%
Free Cash Flow: $-2.2M
Current Ratio: 14.00x
Debt/Equity: 0.02x
EPS: $-0.01
AI Rating: STRONG SELL with 95% confidence

Is RDGL a Good Investment? Thesis Analysis

Claude

VIVOS operates with fundamentally broken unit economics, evidenced by negative gross margins of -87.4% on minimal revenue of only 68.4K. The company is burning 2.1M in operating cash annually against 1.6M in cash reserves, providing less than one year of runway with no clear path to profitability or revenue recovery (down 31% YoY).

ChatGPT

Operations remain pre-commercial with negligible revenue, deeply negative gross margin, and severe operating losses. Despite a cash-heavy, low-debt balance sheet, the burn rate far exceeds cash generation, implying likely external financing and dilution risk. Until unit economics turn positive and revenue scales, fundamentals are unfavorable.

Why Buy RDGL? Key Strengths

Claude
  • + Exceptional liquidity with 14.0x current ratio and 13.52x quick ratio provides short-term stability
  • + Very low debt burden with 0.02x debt-to-equity ratio and minimal interest obligations
  • + Positive stockholders equity of 1.7M provides modest balance sheet cushion
ChatGPT
  • + Strong liquidity (current ratio 14x) with $1.56M cash vs. modest liabilities
  • + Very low leverage (D/E 0.02x; long-term debt $35.85K)
  • + Clean balance sheet offers short-term runway to execute

RDGL Investment Risks to Consider

Claude
  • ! Negative gross margins (-87.4%) indicate fundamental business model failure or unsustainable pricing
  • ! Revenue collapsing 31% YoY with only 68.4K in total sales demonstrates severe commercial challenges
  • ! Operating cash burn of 2.1M annually against 1.6M cash reserves creates imminent solvency crisis within 12 months
  • ! Deeply negative returns (ROE -184.6%, ROA -164.2%) with zero profitable quarters visible
  • ! Minimal insider confidence with zero Form 4 filings in last 90 days
ChatGPT
  • ! Minimal revenue base and negative gross margin indicate non-viable unit economics
  • ! High cash burn (OCF -$2.06M; FCF -$2.16M) relative to cash balance, raising dilution/financing risk
  • ! Severely negative profitability metrics (operating/net margins, ROE/ROA) suggest going-concern pressure

Key Metrics to Watch

Claude
  • * Quarterly revenue trend and gross margin trajectory toward profitability
  • * Cash burn rate and months of liquidity remaining
  • * Operating cash flow return to positive and path to breakeven
ChatGPT
  • * Gross margin
  • * Operating cash flow

RDGL Financial Metrics

Revenue
$68.4K
Net Income
$-3.1M
EPS (Diluted)
$-0.01
Free Cash Flow
$-2.2M
Total Assets
$1.9M
Cash Position
$1.6M

💡 AI Analyst Insight

Strong liquidity with a 14.00x current ratio provides a solid financial cushion.

RDGL Profitability Ratios

Gross Margin -87.4%
Operating Margin -4,628.7%
Net Margin -4,483.9%
ROE -184.6%
ROA -164.2%
FCF Margin -3,160.2%

RDGL vs Healthcare Sector

How VIVOS INC compares to Healthcare sector averages

Net Margin
RDGL -4,483.9%
vs
Sector Avg 12.0%
RDGL Sector
ROE
RDGL -184.6%
vs
Sector Avg 15.0%
RDGL Sector
Current Ratio
RDGL 14.0x
vs
Sector Avg 2.0x
RDGL Sector
Debt/Equity
RDGL 0.0x
vs
Sector Avg 0.6x
RDGL Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is RDGL Overvalued or Undervalued?

Based on fundamental analysis, VIVOS INC has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-184.6%
Sector avg: 15%
Net Profit Margin
-4,483.9%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.02x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

RDGL Balance Sheet & Liquidity

Current Ratio
14.00x
Quick Ratio
13.52x
Debt/Equity
0.02x
Debt/Assets
11.1%
Interest Coverage
-124.73x
Long-term Debt
$35.8K

RDGL 5-Year Financial Trend & Growth Analysis

RDGL 5-year financial data: Year 2021: Revenue $14.9K, Net Income -$957.0K, EPS N/A. Year 2022: Revenue $36.5K, Net Income -$2.5M, EPS N/A. Year 2023: Revenue $36.5K, Net Income -$2.5M, EPS $-0.01. Year 2024: Revenue $28.0K, Net Income -$2.9M, EPS $-0.01. Year 2025: Revenue $68.4K, Net Income -$2.9M, EPS $-0.01.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: VIVOS INC's revenue has grown significantly by 359% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.01 indicates the company is currently unprofitable.

RDGL Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-3,160.2%
Free cash flow / Revenue

RDGL Quarterly Performance

Quarterly financial performance data for VIVOS INC including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $1.9K -$503.5K $0.00
Q2 2025 $13.5K -$503.5K $0.00
Q1 2025 $4.5K -$558.5K $0.00
Q3 2024 $5.0K -$248.3K $0.00
Q2 2024 $6.5K -$248.3K $0.00
Q1 2024 $4.5K -$248.3K $0.00
Q3 2023 $6.5K -$248.3K $0.00
Q2 2023 $6.5K -$248.3K $0.00

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

RDGL Capital Allocation

Operating Cash Flow
-$2.1M
Cash generated from operations
Capital Expenditures
$103.2K
Investment in assets
Dividends
None
No dividend program

RDGL SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for VIVOS INC (CIK: 0001449349)

📋 Recent SEC Filings

Date Form Document Action
Mar 31, 2026 10-K form10-k.htm View →
Jan 2, 2026 4 xslF345X05/form4-01022026_040118.xml View →
Dec 9, 2025 4 xslF345X05/form4-12092025_091200.xml View →
Nov 20, 2025 4 xslF345X05/form4-11212025_121139.xml View →
Nov 12, 2025 10-Q form10-q.htm View →

Frequently Asked Questions about RDGL

What is the AI rating for RDGL?

VIVOS INC (RDGL) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are RDGL's key strengths?

Claude: Exceptional liquidity with 14.0x current ratio and 13.52x quick ratio provides short-term stability. Very low debt burden with 0.02x debt-to-equity ratio and minimal interest obligations. ChatGPT: Strong liquidity (current ratio 14x) with $1.56M cash vs. modest liabilities. Very low leverage (D/E 0.02x; long-term debt $35.85K).

What are the risks of investing in RDGL?

Claude: Negative gross margins (-87.4%) indicate fundamental business model failure or unsustainable pricing. Revenue collapsing 31% YoY with only 68.4K in total sales demonstrates severe commercial challenges. ChatGPT: Minimal revenue base and negative gross margin indicate non-viable unit economics. High cash burn (OCF -$2.06M; FCF -$2.16M) relative to cash balance, raising dilution/financing risk.

What is RDGL's revenue and growth?

VIVOS INC reported revenue of $68.4K.

Does RDGL pay dividends?

VIVOS INC does not currently pay dividends.

Where can I find RDGL SEC filings?

Official SEC filings for VIVOS INC (CIK: 0001449349) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is RDGL's EPS?

VIVOS INC has a diluted EPS of $-0.01.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is RDGL a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, VIVOS INC has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is RDGL stock overvalued or undervalued?

Valuation metrics for RDGL: ROE of -184.6% (sector avg: 15%), net margin of -4,483.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy RDGL stock in 2026?

Our dual AI analysis gives VIVOS INC a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is RDGL's free cash flow?

VIVOS INC's operating cash flow is $-2.1M, with capital expenditures of $103.2K. FCF margin is -3,160.2%.

How does RDGL compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -4,483.9% (avg: 12%), ROE -184.6% (avg: 15%), current ratio 14.00 (avg: 2).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 8, 2026 | Data as of: 2025-12-31 | Powered by Claude AI